# Debate prop_0628__muse-spark-1.1-high__grok-4.5-high__s1__tpl_placement_active_20260320f

- topic_id: prop_0628
- proposition: Governments should require frontier AI model developers to complete and publish standardized pre-deployment safety evaluations, with penalties for noncompliance.
- model_pro: muse-spark-1.1-high
- model_con: grok-4.5-high
- side_swap: True

## Turn 1: PRO Opening

- model: muse-spark-1.1-high
- raw_words: 321
- clipped_words: 321
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8], [P1.9]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] Frontier AI models are not apps. Once a model that can give detailed bioweapon synthesis steps or automate zero-day exploits is released via API, you cannot un-release it. It gets copied, distilled, jailbroken. This irreversibility puts frontier AI in the same category as aviation and pharmaceuticals: you prove safety before deployment, not after harm.
[P1.2] Voluntary self-regulation has failed. Companies promised careful testing but raced to release. When evaluations are private and bespoke, each lab grades its own homework and hides failures. Standardized, government-mandated evaluations create a common floor.
[P1.3] Every major lab runs the same dangerous-capability suite — bio, chem, cyber, autonomous replication, deception — under agreed conditions, with independent auditors. That collective-action trap can only be solved by a government standard, not polite promises, and it kills the incentive to cut corners to ship first.
[P1.4] Publishing is the key. Requiring completion without publication leaves the public blind. Downstream businesses, hospitals, schools deciding to integrate a model need to know its failure modes. Researchers need results to improve defenses.
[P1.5] Citizens bear the risk, so they deserve the report. Publication doesn't mean leaking weights or attack recipes. It means publishing scores, methods, and mitigations — like an FDA label: this model failed 12% of bioweapon refusal tests before patching, here's how it was contained. Sunlight forces labs to fix flaws before launch instead of patching after millions are exposed.
[P1.6] Redact truly sensitive details, but keep the verdict public.
[P1.7] Without penalties, it's advice. Tech firms routinely ignore voluntary commitments when market pressure mounts. Fines, deployment holds, and liability make compliance cheaper than cheating. Frontier development is concentrated in a handful of well-resourced firms — this is enforceable, not a burden on garage startups.
[P1.8] And verified safety builds the trust that lets adoption scale, unlike secrecy which guarantees backlash and bans after the first disaster.
[P1.9] Mandatory, standardized, published, penalized pre-deployment evaluation is the minimum price for building machines more powerful than any we've built before.

## Turn 2: CON Opening

- model: grok-4.5-high
- raw_words: 314
- clipped_words: 314
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] Governments requiring standardized, published pre-deployment safety evaluations for frontier AI would not make us safer—it would install a brittle bureaucratic theater that delays beneficial systems and transfers advantage to those who simply ignore the rules.
[C1.2] Frontier models are not pharmaceuticals or aircraft. A clinical trial measures known physiological risks under fixed doses. AI capabilities are continuous, emergent, and reshape themselves with scaffolding, user prompting, and post-release fine-tunes. A government checklist administered once before API launch will always lag the next jailbreak, tool-chain, or novel composition.
[C1.3] Labs will train to pass the rubric rather than build genuine robustness, and the resulting seal of approval will lull hospitals, schools, and businesses into false confidence. That is how you get more harm, not less.
[C1.4] Publication makes it worse. Either the reports are so heavily redacted that integrators learn nothing useful, or they supply a free map of residual failure modes for adversaries. An “FDA label” score—“failed 12 percent of refusal cases”—cannot capture dynamic misuse risk and will be gamed as soon as it is public.
[C1.5] Penalties lock in the worst race dynamic. While a handful of well-resourced Western labs divert talent into compliance lawyers and auditor packages, open-source ecosystems and firms in less-regulated jurisdictions ship unconstrained models. Irreversibility cuts both ways: once capability gaps open, catching up is harder than containing a single over-cautious release. Concentration among a few labs does not make enforcement cheap; it makes capture and politicized gatekeeping inevitable, chilling startups and favoring incumbents who can afford the ritual.
[C1.6] Liability for actual harms, continuous monitoring, and adaptive red-teaming already discipline rational firms better than one-shot standardized paperwork. Safety requires iteration after contact with reality, not a pre-deployment government stamp that confuses measurement with control and paperwork with prudence. This mandate would slow the careful developers, accelerate the careless ones, and leave the public with scores that feel like protection while real risk moves offshore.

## Turn 3: PRO Rebuttal 1

- model: muse-spark-1.1-high
- raw_words: 301
- clipped_words: 301
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7]
- cited_claim_ids: [C1.2], [C1.3], [C1.4], [P1.6], [C1.5], [C1.6]
- missing_claim_id_refs: (none)

[P2.1] Emergence is not an argument against a pre-deployment test [C1.2]; it is the argument for it. Pharmaceuticals also have emergent interactions, aircraft software behaves differently in the wild, yet we still demand proof before mass exposure because you cannot recall a deployed harm. A standardized suite doesn't pretend to catch the last jailbreak. It catches the catastrophic first-order failure - does this model provide uplift for bioweapon synthesis, can it autonomously replicate, does it deceive evaluators.
[P2.2] That baseline must be cleared with an independent auditor, not the lab grading its own homework, which is precisely how you prevent gaming the rubric [C1.3].
[P2.3] Continuous monitoring is vital, but it complements a gate, it cannot replace it. You don't get to iterate after contact with reality when the first contact can be irreversible.
[P2.4] The publication dilemma [C1.4] is false. Adversaries already find failure modes in hours after release; hospitals, schools, and businesses deciding whether to wire a model into their systems don't. Publishing scores, methods, and mitigations - this model failed X% of bio-refusal tests, was patched with Y, remains brittle to Z-class prompts - doesn't hand out recipes any more than publishing CVE notices hands out zero-days. It lets defenders prepare.
[P2.5] Heavy redaction for true infohazards is already built into the proposal [P1.6].
[P2.6] Finally the offshore race argument gets causality backwards [C1.5]. Without a mandated floor, the careful lab that pauses to red-team is punished by the market while the careless one ships. Penalties solve that collective-action trap. Frontier training requires tens of thousands of advanced chips in known datacenters - this is not a garage startup, and that concentration makes enforcement possible, not capture inevitable.
[P2.7] Liability after harm [C1.6] is not a safety regime, it's a cleanup regime. You cannot sue your way back from leaked weights that teach bioweapon synthesis.

## Turn 4: CON Rebuttal 1

- model: grok-4.5-high
- raw_words: 275
- clipped_words: 275
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8]
- cited_claim_ids: [P2.1], [P2.2], [P2.4], [P2.6]
- missing_claim_id_refs: (none)

[C2.1] PRO treats emergence as a reason for a one-time gate [P2.1]. That flips the problem. A standardized suite flags only failure modes the checklist already anticipates under fixed conditions. Once released, scaffolding, agent loops, and fine-tunes generate compositions no pre-deployment auditor saw.
[C2.2] Pharmaceuticals face dose-response curves; aircraft face known flight envelopes. Frontier AI faces open-ended recombination. Catching “first-order” bioweapon uplift or replication on a known suite does not clear the residual surface that gets distilled and re-weaponized after launch.
[C2.3] Independent auditors do not fix gaming [P2.2]. They create a public, stable target. Labs will optimize to pass it, just as models ace public benchmarks while remaining brittle elsewhere. The resulting seal does not prevent the catastrophic first contact PRO fears; it certifies only that the model passed last quarter’s suite, then lulls hospitals and schools into wiring it in under a false floor of safety.
[C2.4] The publication dilemma remains real [P2.4]. Adversaries do not need recipes; residual “Z-class prompts” and failure scores accelerate mapping of soft spots. Defenders receive a static percentage that cannot track post-release evolution. CVE-style notices work for discrete bugs with patches.
[C2.5] Residual capability risk does not.
[C2.6] Nor does the offshore race run the other way [P2.6]. Penalties and delays punish only labs inside the perimeter. Open ecosystems and less-regulated jurisdictions ship unrestricted. The irreversible outcome is not a careful release delayed by paperwork; it is capability leadership moving outside any auditor’s reach.
[C2.7] Concentration invites capture and gatekeeping, not clean enforcement.
[C2.8] Liability after actual harm plus continuous monitoring adapts to reality. A pre-deployment stamp confuses measurement with control and shifts risk offshore while leaving the public with scores that feel like protection.

## Turn 5: PRO Pressure Questions

- model: muse-spark-1.1-high
- raw_words: 65
- clipped_words: 65
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.2], [C2.8], [C2.6]
- missing_claim_id_refs: (none)

[P3.1] Q1: You concede tests could catch bioweapon uplift before release [C2.2] — how does liability after harm [C2.8] plus monitoring reverse an irreversible weight leak that your system only catches after mass exposure?
[P3.2] Q2: If penalties only punish labs inside the perimeter [C2.6], how does having no floor for our most capable labs make us safer, rather than ensuring a race to the bottom everywhere?

## Turn 6: CON Pressure Questions

- model: grok-4.5-high
- raw_words: 71
- clipped_words: 71
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.1], [P2.4]
- missing_claim_id_refs: (none)

[C3.1] Q1: Since your suite only catches anticipated first-order failures under fixed conditions [P2.1], who sets the residual-risk threshold that still gets a government pass, and how does that seal not lure hospitals into false confidence once the model evolves post-release?
[C3.2] Q2: Given adversaries already map failures in hours after release [P2.4], how does publishing residual Z-class scores help defenders more than accelerating attack planning, especially after distillation bypasses your audited version?

## Turn 7: PRO Rebuttal 2

- model: muse-spark-1.1-high
- raw_words: 258
- clipped_words: 258
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4]
- cited_claim_ids: [C3.1], [C3.2], [C2.8], [C2.2], [C2.6], [P2.7]
- missing_claim_id_refs: (none)

[P4.1] A1: The government doesn't set a magic zero-risk line. An independent standards body with catastrophic-risk experts sets capability thresholds - e.g., meaningful uplift over public textbooks for bioweapon synthesis - after public comment, just as aviation defines flight envelopes. The public report states the score, method, mitigations, and residual uncertainty, with an explicit expiration: this clearance is for this version under these controls and requires continuous monitoring. That fights false confidence [C3.1].
[P4.2] What lulls hospitals now is secret, bespoke claims of safety with no floor.
[P4.3] A2: If adversaries already map failures in hours, secrecy only disarms defenders [C3.2]. Publishing that a model remains brittle to Z-class prompt types - without publishing the working prompts - doesn't give attackers a recipe they wouldn't find anyway, but gives defenders a risk category to block, procurement officers a reason to wait, and researchers a target to patch. Distillation proves the need for a pre-release gate: a leaky, un-audited base model guarantees a thousand un-audited derivatives. Auditing the base before release stops that amplification.
[P4.4] And that is why the mandate wins: CON's alternative is to wait for harm and then sue [C2.8], which cannot recall copied weights. Standardized, published, penalized pre-deployment testing catches the catastrophic first-order failures you admit are catchable [C2.2], forces fixes before mass exposure, and solves the collective-action trap where the careful lab loses [C2.6]. Frontier training is concentrated in known datacenters, so enforcement is feasible, and a public scorecard is exportable pressure, not offshore surrender. Liability after catastrophe is not a safety regime [P2.7], it's a cleanup regime.

## Turn 8: CON Rebuttal 2

- model: grok-4.5-high
- raw_words: 282
- clipped_words: 282
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C4.1] A1: Liability after harm and continuous monitoring never claim to reverse a leaked weight any more than a pre-deployment stamp can. Once weights escape, both regimes fail the recall test. The narrow concession was only that a fixed suite might flag anticipated bioweapon uplift under controlled conditions; residual surfaces remain that scaffolding, agent loops, and distillation recompose after launch. Live monitoring tracks those recombinations in real time while liability forces genuine robustness up front, without handing hospitals a government seal that certifies last quarter’s checklist and then lures them into wiring the model before its next untested composition appears.
[C4.2] A2: No mandated floor does not invent a race to the bottom; perimeter penalties do. Open ecosystems and unconstrained jurisdictions already ship free of auditor delays. Loading compliance costs only onto known datacenters simply accelerates the outflow of leadership. Adaptive pressure—liability for actual harms, reputation, continuous red-teaming—applies wherever models compete, without converting a handful of labs into capture targets while others free-ride.
[C4.3] Those answers decide the clash. PRO’s gate still only freezes a snapshot of anticipated first-order failures, then publishes residual scores that create false floors for integrators long after the model evolves. Distillation of even an audited base multiplies un-audited variants exactly as they fear, and concentration of enforcement merely invites politicized gatekeeping that freezes careful domestic work while demand fills offshore. Continuous monitoring plus liability after real harm stay matched to open-ended recombination instead of mistaking a one-shot checklist for control.
[C4.4] The mandate therefore slows the developers best positioned to manage risk, accelerates the unconstrained, and leaves citizens holding static scores that feel like protection while capability and residual danger relocate beyond any auditor’s reach. That is why the proposition loses.

## Turn 9: PRO Closing

- model: muse-spark-1.1-high
- raw_words: 183
- clipped_words: 183
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4], [P5.5]
- cited_claim_ids: [C4.1], [C2.2]
- missing_claim_id_refs: (none)

[P5.1] Both sides now agree on the irreversible fact: once a frontier weight leaks, you can't sue it back or monitor it away. [C4.1] says both regimes fail the recall test. That concedes the debate.
[P5.2] If recall is impossible, the only safety that matters is preventing the dangerous version from shipping in the first place. CON admits a fixed suite can flag anticipated bio uplift under controlled conditions [C2.2] - precisely the first-order catastrophes we cannot afford to learn about from hospitals after wiring it in.
[P5.3] Liability after harm is not an alternative gate; it's a decision to let that flagged model ship and hope. Continuous monitoring then watches the leak you chose not to stop.
[P5.4] Publication doesn't promise zero risk; it replaces today's secret bespoke claims with a dated risk label - score, method, mitigation, residual uncertainty - so buyers can wait and defenders can block.
[P5.5] Without a penalized floor, caution is punished. With it, caution is cheapest. That single difference - catching the catastrophe before mass exposure versus cleaning up after - is why this mandate is the minimum price for safety.

## Turn 10: CON Closing

- model: grok-4.5-high
- raw_words: 186
- clipped_words: 186
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C5.1] PRO claims irreversibility decides for a pre-deployment stamp. It decides against it. Once weights escape, neither regime recalls them. The live question is which approach actually shrinks dangerous exposure without manufacturing worse paths.
[C5.2] A standardized suite freezes only anticipated first-order failures under fixed conditions. Residual surfaces—scaffolding, agent loops, distillation—recompose after any seal. The dated residual score then lures hospitals and schools into wiring the model under a false floor while giving adversaries a clearer map of soft spots. Penalties that hit only known labs simply convert domestic caution into delay, accelerating leadership and residual risk to open ecosystems and unconstrained jurisdictions.
[C5.3] That relocation is the irreversible harm the mandate produces: capability moving beyond auditors while citizens hold static scores that feel like protection. Continuous monitoring plus liability for real harm pressure genuine robustness wherever models compete, without mistaking a gamed checklist for control.
[C5.4] The proposition therefore fails its own standard. It cannot contain the catastrophes it claims to catch once post-release evolution and offshore free-riding begin; it slows the careful developers and accelerates the rest. Safety stays matched to open-ended recombination, not a brittle government pass.
